Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPFFR1 | Q9GZQ6 | 6/20 | 0.52 |
| ▸ | NPFFR2 | Q9Y5X5 | 6/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | HTR7 | P34969 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7618700 | 0.87 | NPFFR1 (0.52) | NPFFR1NPFFR2CYP2D6ALDH1A1OPRK1 | |
| SCHEMBL7625331 | 0.82 | NPFFR1 (0.51) | NPFFR1NPFFR2OPRK1HTR1AHTR7 | |
| SCHEMBL7644663 | 0.82 | NPFFR1 (0.53) | NPFFR1NPFFR2OPRK1HTR1AHTR7 | |
| SCHEMBL7251032 | 0.81 | NPFFR1 (0.56) | NPFFR1NPFFR2CYP2D6ALDH1A1OPRK1 | |
| SCHEMBL7625460 | 0.81 | SIGMAR1 (0.49) | NPFFR1NPFFR2CYP2D6ALDH1A1KDM4E | |
| SCHEMBL9146667 | 0.78 | OPRM1 (0.50) | NPFFR1NPFFR2ALDH1A1OPRK1 | |
| SCHEMBL7621104 | 0.77 | OPRM1 (0.48) | CYP2D6ALDH1A1KDM4ESIGMAR1 | |
| SCHEMBL7627376 | 0.77 | DRD4 (0.52) | CYP2D6SIGMAR1 | |
| SCHEMBL3937184 | 0.77 | NPFFR1 (0.66) | NPFFR1NPFFR2CYP2D6ALDH1A1 | |
| SCHEMBL6663595 | 0.77 | ALDH1A1 (0.43) | NPFFR1NPFFR2CYP2D6ALDH1A1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6444677-B2 | TREATMENT OF INFLAMMATION, CARDIOVASCULAR DISEASE, PAIN, ETC. | PFIZER INC. | 2002-09-03 | — | — | US | disclosed |
| US-20010046993-A1 | 5-memberd heteroaryl substituted 1,4-dihydropyridine compounds as bradykinin antagonists | IKEDA TAKAFUMI (JP) | 2001-11-29 | — | — | US | disclosed |
| EP-1106614-A1 | 5-Membered heteroaryl substituted 1,4-dihydropyridine compounds as bradykinin antagonists | PFIZER INC. (US) | 2001-06-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010046993-A1 | 5-memberd heteroaryl substituted 1,4-dihydropyridine compounds as bradykinin antagonists | BDKRB1, BDKRB2, CNR2 | NPFFR1 700/4885NPFFR2 721/4885CYP2D6 716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.